Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients

J Transl Med. 2014 Feb 24:12:54. doi: 10.1186/1479-5876-12-54.


Background: Tumor Associated Antigens are characterized by spontaneous immune response in cancer patients as a consequence of overexpression and epitope-presentation on MHC class I/II machinery. Matrix Metalloprotease 11 (MMP11) expression has been associated with poor prognosis for several cancer types, including breast and prostate cancer.

Methods: MMP11 expression was determined by immunoistochemistry in breast and prostate cancer samples. Circulating MMP11 protein as well as the spontaneous immune responses against MMP11 were analyzed in a set of breast and prostate cancer patients.

Results: In plasma samples MMP11 protein was present in 5/13 breast cancer patients and in 1/12 prostate cancer patients. An antibody response was observed in 7/13 breast cancer patients and in 3/12 prostate cancer patients.

Conclusions: These findings further suggest MMP11 as a promising biomarker for these tumor types and a suitable target for cancer immunotherapy strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neoplasm / blood*
  • Antibody Formation / immunology*
  • Breast Neoplasms / blood
  • Breast Neoplasms / enzymology*
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / pathology
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 11 / blood*
  • Matrix Metalloproteinase 11 / immunology
  • Neoplasm Invasiveness
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / enzymology*
  • Prostatic Neoplasms / immunology*
  • Prostatic Neoplasms / pathology
  • Treatment Outcome


  • Antibodies, Neoplasm
  • MMP11 protein, human
  • Matrix Metalloproteinase 11